⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CGTX News
Cognition Therapeutics, Inc. Common Stock
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
globenewswire.com
CGTX
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference
globenewswire.com
CGTX
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
globenewswire.com
CGTX
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
globenewswire.com
CGTX